Based on the therapeutic efficacy and unknown mechanism of anti-VEGF-A antibody, bevacizumab, in rescuing SNHL in some NF2 patients with VS3, we explored whether exogenous VEGF-A application to cochlear explants could be toxic. This evidence concerns the gene VEGFA and NF2-related schwannomatosis.